EGF and neoplasm: The first experiments demonstrating the ability to redirect CRAds towards tumor cells were performed using dual-virus mixtures consisting of a CRAd and an adenovirus secreting a bispecific adapter protein consisting of a fusion between the soluble CAR receptor and the EGF ligand [91].